Antileukoproteinase Antibodies

Antileukoproteinase (SLPI)

Acid-stable proteinase inhibitor with strong affinities for trypsin, chymotrypsin, elastase, and cathepsin G (PubMed:3533531, PubMed:3462719, PubMed:2039600, PubMed:2110563, PubMed:10702419, PubMed:24121345). Modulates the inflammatory and immune responses after bacterial infection, and after infection by the intracellular parasite L.

major. Down-regulates responses to bacterial lipopolysaccharide (LPS) (By similarity).

Gene Information

Human
Gene Name:	SLPI
Uniprot:	P03973
Entrez:	6590

Family

Belongs to:
No superfamily

Alternative Names

ALK1; ALPProtease inhibitor WAP4; antileukoproteinase; BLPISeminal proteinase inhibitor; HUSI; HUSI-I; Mucus proteinase inhibitor; secretory leukocyte peptidase inhibitor; secretory leukocyte protease inhibitor (antileukoproteinase); Secretory leukocyte protease inhibitor; SLPI; WAP four-disulfide core domain protein 4; WAP4HUSI-1; WFDC4MPI

Molecular Weight

Mass (kDA):
14.326 kDA

Genomic Context

Human
Location:	20q13.12
Sequence:	20; NC_000020.11 (45252239..45254564, complement)

Tissue Specificity

Detected in blood plasma (PubMed:24352879). Detected in bone marrow myeloid cells (PubMed:24352879). Detected in airway sputum (PubMed:2039600). Detected in parotid gland secretions (PubMed:3462719). Detected in seminal plasma (at protein level) (PubMed:3485543). Detected in uterus cervix (PubMed:3533531).

Subcellular Localizations

Secreted.

Diseases

• Inflammation
• Lung Diseases
• Malignant Neoplasms
• Neoplasms
• Hiv Infections
• Chronic Obstructive Airway Disease
• Carcinoma
• Fibrosis
• Immunologic Deficiency Syndromes
• Cystic Fibrosis
• Infective Disorder
• Lung Diseases, Obstructive
• Pulmonary Emphysema

• Pneumonia
• Inflammatory Response
• Malignant Neoplasm Of Ovary
• Neoplasm Metastasis
• Lung Injury
• Ovarian Neoplasm
• Asthma

Interacting Proteins

• FAM9B
• SGTA

Pathways

• Secretion
• Pathogenesis
• Immune Response
• Inflammatory Response
• Wound Healing
• Proteolysis
• Localization
• Innate Immune Response
• Phagocytosis
• Transport
• Cell Growth
• Cell Proliferation
• Coagulation

• Protein Secretion
• Angiogenesis
• Tropism
• Adaptive Immune Response
• Virulence
• Viral Replication
• Acute Inflammatory Response

PTMs

• Cleavage
• Glycosylation
• Oxidation
• Phosphorylation

• Reduction
• Methylation
• Ubiquitination
• Biotinylation

• Acetylation

Research Areas

• Cancer

For details, visit:
bosterbio.com/bosterbio-gene-info-cards/SLPI

Boster Bio - Best Uses Of The SLPI Marker

The SLPI Marker ELISA kits are used to detect soluble proteins. It is widely used in the detection of protein molecules. Boster Bio offers a variety of applications for the SLPI Marker including ELISAs, immunoassays, and biochemical analyses. Researchers can detect proteins in a variety biologic fluids using the SLPI Marker. This includes serum, plasma and urine.

SLPI Marker

SLPI provides local defense against insults as well as antiretroviral/anti-HIV-1 activities. Its presence in the body also contributes to wound healing and confinement of tissue damage. The SLPI biomarker is used in medical settings for monitoring malignant lesions and infections. Its antiviral activity makes it a desirable candidate for a variety of clinical applications.

The NE/SLPI molecule is capable of binding cell membranes. However, it is important to note that the NE-SLPI complex is passively associated with non-biological components and may not bind SLPI as efficiently as SLPI in free solution. Future experiments should incorporate measures to counteract the ability of SLPI to bind non-specifically to CG and NE.

During the validation and development phases of the study, the incidence of AKI varied between 15% and 25%. This is well within the normal range of AKI after cardiac surgery. Of note, the KDIGO diagnostic criterion of oliguria lasting more than 6 h was not met by any of the patients, which may be due to strict counteractive measures. If this is the case, the marker needs to be used more widely.

The SLPI molecule and its complexes have different charges. Cathepsin G (and cathepsin Ne) have the most positively charged compounds. Other proteins had weakly-positive charges on different surfaces. Although the SLPI molecule's neutrality is negligible, it is primarily a positive molecule in the presence NE. Its negative charges are largely neutral. In cellular environments, a high concentration may indicate a high level activity in a particular molecule.

ELISA Kits

The Picokine(r) Quick ELISA kit offers superior sensitivity and consistency while delivering a rapid turnaround time. This ELISA Kit guarantees a positive reaction in a wide range of biological samples. Picokine(r), Quick ELISA kits feature 96-well formats with removable strips. It also uses proprietary trade secrets in order to provide high-sensitivity ELISA kit kits.

Boster Bio's Picokine(r), Fast ELISA Kit uses a micro-titration plates and capture and detection antibodies. In one step, both the detection and capture antibodies form a sandwich compound. The next step is the addition of the Avidin-Biotin-Peroxidase Complex, which acts as the TMB substrate. The target analyte determines the intensity of blue product. PicoKine(r), Quick ELISA Kit is validated against a variety of biological samples including a range targets analytes.

Antibodies

SLPI is a member in the Serpin family. It's expressed primarily by secretory secretory epithelial cells, secretory fluids, and secretory glandular epithelial tissues. It is a potent inhibitor for proteolytic and cell proliferation enzymes. SLPI is not only an inhibitor of proteolysis but also has antiviral or anti-inflammatory capabilities.

SLPI regulates osteoclast function and the microenvironment that surrounds the osteoblast. It is also associated the the degradation IkB13 and the proepithelin16 marker. Therefore, antibodies to SLPI may indicate bone tumorigenesis. Further studies are needed to determine the implication of these antibodies on osteoblast differentiation and bone resorption. The SLPI marker can be used to identify individuals who might benefit from a surgical procedure.

SLPI plays a role in the negative regulation pro-inflammatory cytokine production in human PDL cells. It also determines the cell's susceptibility to LPS. It also regulates the expression levels of MCP-1, IL-6, and basal LPS-stimulated IL-6. The SLPI-SLPI effect on cytokine production is associated with the modulation of TLR2 and TLR4 expression, as well as NF-kB signaling.

SLPI is a pleiotropic and broad-based antimicrobial protein. It inhibits the activity many proteases, including neutrophil-elastase as well as leukocyte–elastase. Its functions in the immune system include preventing excessive inflammation during intestinal homeostasis. Its antiviral activities and anti-HIV-1 activities help to limit damage and accelerate wound healing.

SLPI promotes osteoblast cell proliferation and differentiation. It targets transcription factors that are involved in osteoblast differentiation. Antibodies that recognize SLPI markers may also play a role in osteoporosis. They could be used to help develop therapies for bone diseases. These findings support SLPI's importance in osteoporosis. Therefore, this molecule has an important role in bone regeneration.

Monoclonal antibodies were made to detect SLPI markers in CF-cells. These antibodies were tested against full-length native SLPI and against CF patient sputum samples. They were also tested using an ELISA method at 2000 ng/mL against recombinant CSLPI. Cross-reactivity was less than 0.5%, indicating that the antibodies' specificity for C-SLPI is excellent.

Applications

The SLPI Marker, a biomarker that detects protein-disulphide Iomerase, is a novel biomarker. It is essential for the immune system to recognize this marker. The protein is also thought essential for viral cells invasion. There are currently no functional data available on the role SLPI plays. Although there are numerous hypotheses regarding its function, this research is still at an early stage.

Patients undergoing major surgical procedures are one of the most common uses of SLPI to help with perioperative risk stratification. However, patients who do not have a history of renal dysfunction might not have a high serum creatinine enough to trigger alerts. Additional analysis was not performed on patients with pre-existing renal dysfunction, which improved the accuracy of the test. The results showed that SLPI was a more sensitive and specific biomarker to detect AKI in patients who have not had pre-existing renal disease.

The SLPI protein encoded by the SLPI gene is 12 kDa. This anti-leukocyte protease, or SLPI is expressed by many cell types including macrophages, neutrophils, and other cells. It acts as an non-redundant anti-protease and inhibits immune system serine proteases. SLPI may also have anti-fungal or antibacterial properties.

The SLPI Marker is a promising marker for acute kidney injury following cardiac surgery. Early detection of AKI may lead to an earlier initiation of organ-protective therapies and reduce the incidence of serious complications. However, SLPI cannot be used as a diagnostic biomarker in acute kidney injury. To confirm its accuracy, further clinical studies will be required. In the meantime, the SLPI Marker has many potential applications.